| Collaborations |
|
Athersys, Inc.
Athersys will provide Molecumetics with cell lines expressing up to 12 validated drug targets produced using the RAGE-Validated Targets technology. Molecumetics plans to use its chemistry based "screen-to-IND" technology platform to develop novel small molecule drug candidates against the validated targets. Targets may be licensed by Molecumetics or co-developed with Athersys.
|